[Development of new drugs for urological cancers].
Urological cancers have a variety of biological characteristics. Thus, anti-cancer agents in this field are often developed focusing on the biological characteristics. For example, LH-RH agonist and anti-androgens have been developed for androgen-sensitive prostate cancer, interferons and IL-2 for renal cell cancer, and BCG for superficial bladder cancer. In this manuscript, new agents which are thought to be promising in the urological field, bropirimine for bladder cancer and liarozole for prostate cancer, are briefly introduced.
Akaza
H
H
Dept. of Urology, Institute of Clinical Medicine, University of Tsukuba, Japan.
D000726:Androgen Antagonists / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D007093:Imidazoles; D003596:Cytosine; C033560:bropirimine; C061121:liarozole